How do you choose empiric therapy for community-acquired pneumonia in a previously healthy adult?

Study for the Medical Council of Canada Qualifying Examination (MCCQE) I. Engage with flashcards and multiple-choice questions with detailed feedback. Prepare confidently!

Multiple Choice

How do you choose empiric therapy for community-acquired pneumonia in a previously healthy adult?

In community-acquired pneumonia for a previously healthy adult, the aim is to cover the organisms most likely to cause disease while avoiding unnecessary broad-spectrum therapy. The common bacteria include typical pathogens like Streptococcus pneumoniae and, to a lesser extent, atypical agents such as Mycoplasma pneumoniae and Chlamydophila pneumoniae. Because these pathogens are usually susceptible to narrower, targeted antibiotics, starting with a narrow-spectrum option helps treat the illness effectively while reducing side effects and the risk of promoting antibiotic resistance. A practical approach is to use an agent that covers the typical organism, such as amoxicillin, or an option that also covers atypicals, like doxycycline or a macrolide. This balances adequate coverage with minimizing collateral damage from broader agents. The choice can be guided by local resistance patterns and patient-specific factors. If there are risk factors for drug resistance or comorbidities, or if the patient does not improve, therapy should be adjusted upward toward broader coverage or combination regimens as recommended by local guidelines (for example, amoxicillin-clavulanate or a respiratory fluoroquinolone). Antiviral therapy is not routinely used for bacterial CAP and is reserved for specific viral etiologies. Doing nothing is not appropriate, as CAP typically requires treatment to prevent progression.

In community-acquired pneumonia for a previously healthy adult, the aim is to cover the organisms most likely to cause disease while avoiding unnecessary broad-spectrum therapy. The common bacteria include typical pathogens like Streptococcus pneumoniae and, to a lesser extent, atypical agents such as Mycoplasma pneumoniae and Chlamydophila pneumoniae. Because these pathogens are usually susceptible to narrower, targeted antibiotics, starting with a narrow-spectrum option helps treat the illness effectively while reducing side effects and the risk of promoting antibiotic resistance.

A practical approach is to use an agent that covers the typical organism, such as amoxicillin, or an option that also covers atypicals, like doxycycline or a macrolide. This balances adequate coverage with minimizing collateral damage from broader agents. The choice can be guided by local resistance patterns and patient-specific factors. If there are risk factors for drug resistance or comorbidities, or if the patient does not improve, therapy should be adjusted upward toward broader coverage or combination regimens as recommended by local guidelines (for example, amoxicillin-clavulanate or a respiratory fluoroquinolone).

Antiviral therapy is not routinely used for bacterial CAP and is reserved for specific viral etiologies. Doing nothing is not appropriate, as CAP typically requires treatment to prevent progression.

More practice questions